Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Pharm Gp LSE:OXP London Ordinary Share GB00B3LXPB43 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 1.925p 1.85p 2.00p 1.95p 1.925p 1.925p 279,750.00 12:18:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.7 -3.9 -0.3 - 23.21

Oxford Pharm Gp Share Discussion Threads

Showing 726 to 750 of 750 messages
Chat Pages: 30  29  28  27  26  25  24  23  22  21  20  19  Older
DateSubjectAuthorDiscuss
23/1/2017
11:37
Here we go lads..
donald trumpton
23/1/2017
11:14
More buying today and a good entry point I think. The bears have always been right on this so far and encouraged me to sell this at a much higher price.....however As at 31 December 2016, the Company had net cash of circa GBP21.9 million and remains well funded to pursue its strategy. That is a lot of cash and I am sure other companies may be looking at this. It gives them a lot of flexibility. Their current business may be rubbish indeed but the risk at this price is not what it was at 10p or 8p or whatever.
barnetpeter
18/1/2017
18:27
What a pile of fluff that RNS was. "Specifically, by comparison with generic NSAIDs, OXPzero(TM) Ibuprofen and OXPzero(TM) Naproxen are milder in the GI tract, delivering major reduction in severe GI mucosal damage, significantly mask the bitter taste/burn associated with NSAIDs, and deliver an attractive pharmacokinetic profile with adaptable drug release properties" NSAID are not nice drugs and their adverse effects are mainly (circa 90%)due to systemic effects rather than local GI irritation. They reduce renal perfusion, are GI toxic and and anti-prostacyclin ie can induce throboembolic events. This is due to inhibition of the COX 1 pathway. With NSAIDs you prescribe low and go slow, particularly in the elderly. Look like the release mechanism might improve bioavaialability [my conclusion] ...yawn. Phase 1 clinical trials blah de blah de blah That said they do reduce pain quite well though it doesn't take a fancy release technology to do that. timbo003 your opinion is correct IMVHO.
sleveen
17/1/2017
18:29
Well I certainly respect your technical knowledge timbo - there of course are many different valid sciences & dark arts - in my field this is approaching an area of interest, which if combined with say the right type of news catalyst may well bring the hoards. Rising accumulation conditions aren't quite right yet so keeping an eye. Have a good evening. ATB LM
luckymouse
17/1/2017
18:03
>>>>lucky Mouse I have absolutely no idea where the share price is going in the short term, I just know that the technology (if you can call it that) is fundamentally flawed. I have been saying this for the last 3-4 years, all the way from around 3p, up to 12p and back down again to sub 2p
timbo003
17/1/2017
17:33
Extremely shouty style timbo? Both +ve & -ve. If that bowl breaks 2 its not be the place to be short mind...there is a historic accumulation zone somewhere around here - prob 1.3-1.8 area - any good news in or above that and traders will probably pile in regardless
luckymouse
17/1/2017
16:43
Quite reasonable.
blue sky territory
17/1/2017
16:03
I'm a Buyer today. ..looking for 4p.
10p here we come
17/1/2017
10:08
I agree Timbo I am invested here but feel like these guys have their head in the sand
typhoon
17/1/2017
07:43
Here's the link to the proposed studies: https://clinicaltrials.gov/ct2/show/NCT02974361?term=oxford+pharmascience&rank=3 Grasping at straws still I see Why don't they just give up on this stupid idea and either concentrate on their original core business of taste masking, or return cash to shareholders? Why on earth don't they realise that they cannot have their cake and eat it. Investors should not be seduced by the cash in the bank, as their approach to what they are trying to achieve is totally futile.
timbo003
16/1/2017
16:00
Plenty of Cash in this company according to Balance Sheet. Unless my research is wildly out, I feel that I am happy to buy at these levels. Please let me know if I have missed something. Thanks.
carbon man
10/1/2017
15:09
Oxford Pharmascience remains well-funded to complete this next stage of work on clinical development and the regulatory pathway for its OXPzero(TM) products, as well as the development work on atorvastatin, with cash balances as at 31 October 2016 of circa GBP22.6 million. If the company has got something.....anything.....then its valued at roughly zero. This has been a real dawg.....but we have had big spikes before and I think news is close.
barnetpeter
09/1/2017
20:18
Singers were looking for stock to fill that order late Friday...
bumpa33
09/1/2017
19:42
I've long thought that with all their £££; funds + know-how, it's only a matter of time before something significant occurs here - and more particularly so, given the shareholder base who are unlikely to leave this one just sitting there and treading water, going nowhere. Changes afoot, I feel. f
fillipe
09/1/2017
18:05
Something going on. Obviously somebody knows something to buy £40,000 worth at 1611 hours
nimrod22
09/1/2017
15:25
+ 13.24% so far today....long time since we saw that happening here! f
fillipe
24/11/2016
20:18
Repeat. Wait for 1.20/30sJust wait and pick your entry. Dont follow the other lemmings
dailylarma
21/11/2016
23:44
Its going lower.Let the muppets jump in now1.20s coming. Slowly but surely.
dailylarma
21/11/2016
10:01
The technology is probably worthless, in fact its a liability, as the directors are just going to spend the precious cash on showing that it's worthless. What they should do is downsize the R&D operation, return excess cash to shareholders and to try go grow the existing commercial business (I have been saying this for the last 3 years)
timbo003
18/11/2016
13:30
Bounce time coming imo here guys....way too cheap! Big investors will want there returns at some stage and I'm sure they will get it! Just a matter of being patient and waiting for the news :)
laptop15
18/11/2016
12:43
Back for another small punt
burbelly
17/11/2016
23:30
Yes you did and I sold out many times higher than current price as a result of yr excellent posts. It is good to have an expert on a medical stock and this stock has turned out to be real pie in the sky. The cash is interesting though which is why I still follow this.
barnetpeter
17/11/2016
22:11
Shareholders should take no comfort from the observation that the cash in the bank (at June 30th) is roughly equivalent to the market cap, as the NSAID projects have now been shown to be unviable and the so called Safestat project has even less chance of success in IMO. There is no rationale for Safestat, it's just another whimsical idea from Marcello which will burn shareholder's money. In order for a Statin to exert a therapeutic effect it has to be metabolised in the liver, it is the metabolites which are active, not the statin itself, so delivering the drug to the colon offers no advantage whatsoever. Surely anyone can see that can't they? Furthermore the side effects and the beneficial therapeutic effects are both related to systemic levels of the active metabolites, so you cannot have one without the other. I posted extensively about this three years ago, see this post and links therein for details: http://uk.advfn.com/cmn/fbb/thread.php3?id=25679562&from=345#firstpost
timbo003
17/11/2016
15:05
Just the £22.6m in cash and fully funded ..
tidy 2
17/11/2016
14:59
Naming cash value means nothing unless you really understand the business. All I know are pharmas are hard to understand at the best of times and the small business are cash hungry and before you know it when you think the company has X amount the next Rns shows it's leaked all away.
bigdazzler
Chat Pages: 30  29  28  27  26  25  24  23  22  21  20  19  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170124 13:05:26